Countries
Industry
Startup stage
Startup size
Funding
Impact startup SDGs
Showing: 2298 filtered startups

Vinclude

Our mission is to enable all children and young people to join organized youth activities, regardless of finances or background. We believe it’s a problem for everyone when some children and young people are left out. Vinclude helps by creating digital solutions and connecting partners who want to support sport teams with income to sports clubs that need funding. Our goal is to create win-win situations, where sports teams can focus on sports, and partners get more value from their financial support. The solutions are developed together with selected partners and their invited sport teams.

ForestSAT As

We predict the risk of forest fires in Mediterranean, sub-tropical and temperate forests using Geospatial data and AI. We aim to drive financial resources and data-driven decision-making into the forestland communities to mitigate the risk of wildfires and regenerate forests into resilient biodiverse carbon sinks.

Consigli

Consigli AS develops "self-designing engineers" who will disrupt the way we plan and design the buildings and infrastructure of future society. To achieve this, we develop a SaaS platform/application using different aspects of AI (Artificial Intelligence) like machine learning, mathematical optimization, and NLP. The service platform is developed in close cooperation with large, established real estate companies that provide data and insights.

Secundo

Secundo is on its way to becoming a leading European marketplace for recommerce. Since its establishment, we have had enormous growth in Norway, and we are currently expanding in Europe. We have a healthy economy with a focus on profitable operations. In addition, we have a strategic and skilled board with experienced entrepreneurs and investors. Read more: https://netthandel.no/denne-gjengen-skal-ta-den-ai-styrte-markedsplassen-til-utlandet https://www.shifter.no/nyheter/secundos-ai-styrte-bruktsalg-har-tredoblet-omsetningen-det-siste-halvaret/279980 https://www.finansavisen.no/lordag/gruenderintervjuet/2022/01/28/7807154/markedsplassen-secundo-vil-gjore-kjop-og-salg-enklere-med-algoritmer

Pharmasum Therapeutics AS

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Mitigrate AS

A growing number of natural disasters led to a 2000% increase in climate insurance claims since the 1970s, reaching $630b worldwide in the 2010s. Continued acceleration will lead climate insurance systems to collapse unless prevention is implemented.  Mitigrate is a InsurTech SaaS startup generating fully automated analyses leading to prioritised preventive measures for reducing climate damages on real estate, starting with flooding. Thanks to high-resolution satellite images, our map-based AI models, and optimization algorithms predict how 50+ climate-positive prevention measures can be implemented to reduce risk. Business value stems from reducing risks on individual assets and prioritizing preventive measures within large portfolios of commercial & residential real estate. Since 01/01/23, the EU Taxonomy has made prevention mandatory for insurers throughout Europe. 

Norkon

Norkon is a fast-growing Norwegian technology company specializing in products for the media industry. With our financial market solution Pulse, award-winning gamification platform Fantasy Funds, and our own AI-powered user personalization tool Beakon, we drive user engagement for our customers globally, including Roularta (BE), The Telegraph (UK), Dagens Næringsliv (NOR), Dagbladet Børsen (DK), Handelsblatt (DE) and many more - catering to millions of users every day. Since our inception, we have developed a deep understanding of real-time data and user attraction, engagement, and retention.

FIELDMADE

We are pioneers in the field of 3D printed spare parts. Our core mission is to develop, produce and sell world leading and fully integrated  Additive Manufacturing (AM) solutions for deployed use.   We increase our customers' operability and readiness level, by providing fully self-sustained production labs on site. Our containers may be transported via land, sea or even air. We create innovative solutions to complex problems based on cutting edge AM technology and software solutions.

Agens

Agens has an award-winning team in the field of concept work, design and mobile development. We work hard to make sure your brand comes alive in the right digital channels – wrapped in a refreshing, world-class user experience.    At Agens, we have conceptualized, designed and developed some of the biggest mobile software projects in Scandinavia ever since Steve Jobs pulled the iPhone out of his turtleneck.

Axo Group

On the right you will find the link to our career site -->> Please go to our career site to find open positions: https://career.axogroup.com/ In the career site you will find our current open positions all around the nordic countries. Please go there and apply: https://career.axogroup.com/

Mia Health

Mia Health is on a mission to enable people live healthy lives, by giving unique personalised insights and research-based lifestyle advice, combined with an engaging community for motivation, inspiration and support. Starting with an inspiring physical activity score, we are expanding to more holistic health in the future. At Mia Health we build products where we can change lives and impact public health care costs. Our core is our digital twin – data analysis based on world-leading research. These analysis can help people live longer (8 years) and healthier (quality of life). BUT! If we cannot wrap this knowledge into an attractive application that users understand, trust, and want to use – then we have nothing! UX is a key focus area for Mia Health.

Innofactor

Innofactor is the leading driver of the modern digital organization in the Nordic Countries for its over 1,000 customers in the commercial, public, and third sectors. Innofactor has the widest solution offering and leading know-how in the Microsoft ecosystem in the Nordics. Innofactor has over 500 enthusiastic and motivated top specialists in Finland, Sweden, Denmark, and Norway. The Innofactor Plc share is listed in the technology section of the main list of NASDAQ Helsinki Oy.

North Sea Salt Works

We are a family business located on the island of Gossen in Northwestern Norway. Our goal is to reinvigorate Norway’s centuries old production of sea salt.We are a Norwegian producer of all natural sea salts. Our clean mineral-rich sea and dedication to quality gives our salt its great character, taste and personality. Our Flake Salt HAVSNØ [Snow of the SEA] is available in stores in Norway, Germany and USA and can be tasted in some of the worlds best restaurants.

InterviewCopilot

InterviewCopilot is a privacy-first desktop app that helps candidates answer live interview questions with clarity and confidence. It detects each question in under a second and streams résumé- and job-description-aware guidance into a private overlay that stays outside screen shares. The app works alongside Zoom, Google Meet, Microsoft Teams, and Webex without joining the call as a bot. Candidates use InterviewCopilot for behavioral, technical, coding, case, and system-design interviews. Live transcription preserves conversation context, screen analysis turns coding tasks and diagrams into focused guidance, and structured answer building adapts responses to STAR, technical trade-offs, or case frameworks. InterviewCopilot runs on macOS and Windows and offers unlimited use through a monthly or annual subscription.

Padeia

Padeia helps you make better decisions, showcase success, and drive growth with confidence. We collect, clean and enrich all your important company data from your different SaaS services into one opinionated data model, giving you a single point of truth for insight, foresight and most importantly: a place to deploy your horisontal AI agents.